| Status: Recommended | |||
Conestat alfa (Ruconest®) is recommended as an option for use within NHS Wales for the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | conestat alfa (Ruconest®) | ||
| Formulation | 2100 units powder for solution for injection, 2100 units powder and solvent for solution for injection | ||
| Reference number | 4519 | ||
| Indication | Treatment of acute angioedema attacks in adults, adolescents and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency |
||
| Company | Pharming Group NV | ||
| BNF chapter | Respiratory system | ||
| Submission type | Licence extension for paediatric use | ||
| Status | Recommended | ||
| Advice number | 0921 | ||
| AWMSG meeting date | 19/05/2021 | ||
| Date of issue | 24/05/2021 | ||
| Commercial arrangement | WPAS | ||
| Further information The above advice incorporates and replaces the AWMSG recommendation for conestat alfa (Ruconest®) for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (advice number 1718, originally published October 2018). |
|||